Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 32 | 2024 | 2276 | 5.130 |
Why?
|
DNA Repair | 16 | 2024 | 2038 | 1.940 |
Why?
|
DNA Repair-Deficiency Disorders | 3 | 2024 | 36 | 1.720 |
Why?
|
Prostatic Neoplasms | 34 | 2024 | 11336 | 1.620 |
Why?
|
DNA Damage | 10 | 2023 | 2439 | 1.280 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 8 | 2023 | 106 | 1.110 |
Why?
|
Muscles | 7 | 2023 | 1579 | 1.030 |
Why?
|
Brachytherapy | 8 | 2021 | 1236 | 0.870 |
Why?
|
Anus Neoplasms | 4 | 2024 | 329 | 0.860 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 107 | 0.840 |
Why?
|
Cystectomy | 9 | 2024 | 697 | 0.830 |
Why?
|
Urinary Bladder | 5 | 2023 | 1166 | 0.810 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 202 | 0.750 |
Why?
|
DNA Nucleotidyltransferases | 4 | 2010 | 176 | 0.750 |
Why?
|
Neoplasm Invasiveness | 15 | 2024 | 3617 | 0.740 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2024 | 800 | 0.710 |
Why?
|
Camptothecin | 1 | 2024 | 588 | 0.710 |
Why?
|
Prostatectomy | 9 | 2024 | 1956 | 0.690 |
Why?
|
Radiosurgery | 3 | 2024 | 1342 | 0.650 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 640 | 0.640 |
Why?
|
Antineoplastic Agents | 11 | 2023 | 13591 | 0.600 |
Why?
|
Cisplatin | 10 | 2023 | 1645 | 0.600 |
Why?
|
Mastectomy, Segmental | 2 | 2013 | 972 | 0.580 |
Why?
|
Allergy and Immunology | 1 | 2018 | 175 | 0.560 |
Why?
|
Gene Amplification | 1 | 2021 | 1085 | 0.560 |
Why?
|
Recombination, Genetic | 3 | 2010 | 1526 | 0.490 |
Why?
|
Retinoblastoma | 2 | 2014 | 317 | 0.480 |
Why?
|
Androgen Antagonists | 8 | 2024 | 1442 | 0.480 |
Why?
|
Radiation Oncology | 3 | 2018 | 563 | 0.480 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 801 | 0.470 |
Why?
|
Neoplasms, Second Primary | 4 | 2023 | 1056 | 0.410 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 146 | 0.410 |
Why?
|
Bacterial Proteins | 5 | 2010 | 3824 | 0.410 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 895 | 0.410 |
Why?
|
Genomics | 7 | 2023 | 5790 | 0.400 |
Why?
|
Fanconi Anemia | 1 | 2014 | 324 | 0.380 |
Why?
|
Prostate | 8 | 2024 | 1791 | 0.380 |
Why?
|
Sesquiterpenes | 2 | 2023 | 176 | 0.380 |
Why?
|
Mutation | 19 | 2024 | 29915 | 0.380 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3574 | 0.370 |
Why?
|
Neoplasm Staging | 13 | 2024 | 11152 | 0.370 |
Why?
|
Humans | 102 | 2024 | 758406 | 0.360 |
Why?
|
DNA | 6 | 2024 | 7199 | 0.360 |
Why?
|
Salvage Therapy | 1 | 2016 | 1268 | 0.350 |
Why?
|
Urologic Neoplasms | 3 | 2019 | 320 | 0.340 |
Why?
|
Prostate-Specific Antigen | 7 | 2022 | 2528 | 0.330 |
Why?
|
Deglutition | 1 | 2010 | 208 | 0.330 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4023 | 0.320 |
Why?
|
Mutation, Missense | 1 | 2018 | 2564 | 0.320 |
Why?
|
Neoplasms | 7 | 2024 | 22032 | 0.310 |
Why?
|
Immunotherapy | 6 | 2024 | 4641 | 0.310 |
Why?
|
Laryngeal Neoplasms | 1 | 2012 | 514 | 0.310 |
Why?
|
BRCA2 Protein | 5 | 2023 | 798 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11709 | 0.300 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2023 | 425 | 0.300 |
Why?
|
Germ-Line Mutation | 4 | 2022 | 1840 | 0.290 |
Why?
|
Models, Molecular | 6 | 2014 | 5410 | 0.290 |
Why?
|
Computational Biology | 2 | 2019 | 3502 | 0.290 |
Why?
|
Genes, BRCA2 | 4 | 2023 | 603 | 0.280 |
Why?
|
Education, Medical | 1 | 2018 | 1725 | 0.280 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 3442 | 0.270 |
Why?
|
Watchful Waiting | 3 | 2019 | 509 | 0.270 |
Why?
|
Disease-Free Survival | 8 | 2024 | 6821 | 0.270 |
Why?
|
Patient Preference | 1 | 2013 | 921 | 0.260 |
Why?
|
Cell Cycle | 1 | 2014 | 2930 | 0.260 |
Why?
|
Speech | 1 | 2010 | 550 | 0.260 |
Why?
|
Male | 59 | 2024 | 358747 | 0.250 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2018 | 1791 | 0.250 |
Why?
|
Protein Multimerization | 1 | 2010 | 979 | 0.250 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 428 | 0.250 |
Why?
|
Borrelia burgdorferi | 1 | 2007 | 183 | 0.250 |
Why?
|
Breast Neoplasms | 4 | 2019 | 21017 | 0.250 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1147 | 0.240 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 546 | 0.220 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2023 | 5249 | 0.220 |
Why?
|
Biomedical Research | 1 | 2018 | 3418 | 0.210 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13245 | 0.210 |
Why?
|
Aged | 38 | 2024 | 168218 | 0.210 |
Why?
|
Seminoma | 1 | 2023 | 134 | 0.200 |
Why?
|
Combined Modality Therapy | 6 | 2024 | 8530 | 0.200 |
Why?
|
DNA, Bacterial | 1 | 2007 | 1456 | 0.200 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3840 | 0.200 |
Why?
|
Recombinases | 2 | 2013 | 66 | 0.200 |
Why?
|
Radiotherapy | 2 | 2019 | 1504 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9273 | 0.190 |
Why?
|
Cell Line, Tumor | 5 | 2021 | 16886 | 0.190 |
Why?
|
Organs at Risk | 2 | 2014 | 358 | 0.190 |
Why?
|
Tumor Burden | 2 | 2024 | 1893 | 0.190 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2013 | 881 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 698 | 0.190 |
Why?
|
DNA-Binding Proteins | 3 | 2020 | 9574 | 0.190 |
Why?
|
Radiotherapy Dosage | 4 | 2019 | 2896 | 0.180 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1612 | 0.180 |
Why?
|
Retrospective Studies | 24 | 2024 | 80168 | 0.180 |
Why?
|
Survival Analysis | 6 | 2020 | 10112 | 0.170 |
Why?
|
Prognosis | 14 | 2024 | 29557 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 631 | 0.160 |
Why?
|
Genes, Neoplasm | 2 | 2017 | 370 | 0.160 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3609 | 0.160 |
Why?
|
Ultraviolet Rays | 2 | 2023 | 1076 | 0.160 |
Why?
|
GTP Phosphohydrolases | 1 | 2021 | 517 | 0.150 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 494 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 219 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 117 | 0.150 |
Why?
|
DNA Polymerase III | 1 | 2018 | 51 | 0.150 |
Why?
|
Treatment Outcome | 14 | 2023 | 64378 | 0.150 |
Why?
|
Serine | 2 | 2013 | 828 | 0.150 |
Why?
|
Middle Aged | 32 | 2024 | 219568 | 0.150 |
Why?
|
Microsatellite Instability | 2 | 2018 | 715 | 0.150 |
Why?
|
DNA Polymerase II | 1 | 2018 | 104 | 0.150 |
Why?
|
Signal Transduction | 3 | 2023 | 23342 | 0.150 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 2012 | 0.140 |
Why?
|
Carcinoma | 2 | 2019 | 2330 | 0.140 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2019 | 607 | 0.140 |
Why?
|
Testicular Neoplasms | 1 | 2023 | 801 | 0.140 |
Why?
|
Female | 31 | 2024 | 390323 | 0.140 |
Why?
|
Aged, 80 and over | 15 | 2024 | 58683 | 0.140 |
Why?
|
Kallikreins | 1 | 2018 | 230 | 0.140 |
Why?
|
INDEL Mutation | 1 | 2017 | 266 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2024 | 949 | 0.130 |
Why?
|
Head and Neck Neoplasms | 1 | 2010 | 2882 | 0.130 |
Why?
|
Travel | 2 | 2021 | 785 | 0.130 |
Why?
|
Dimerization | 2 | 2008 | 888 | 0.130 |
Why?
|
DNA Mutational Analysis | 3 | 2018 | 4106 | 0.130 |
Why?
|
Neoadjuvant Therapy | 6 | 2024 | 2821 | 0.120 |
Why?
|
Microsatellite Repeats | 1 | 2017 | 785 | 0.120 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1074 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 346 | 0.120 |
Why?
|
Neuropeptides | 1 | 2020 | 943 | 0.120 |
Why?
|
Follow-Up Studies | 8 | 2021 | 39059 | 0.120 |
Why?
|
Databases, Factual | 6 | 2019 | 7980 | 0.120 |
Why?
|
Radiation Tolerance | 1 | 2016 | 480 | 0.120 |
Why?
|
Protein Conformation | 4 | 2014 | 3966 | 0.110 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1825 | 0.110 |
Why?
|
Quality of Life | 2 | 2013 | 13285 | 0.110 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1725 | 0.110 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 650 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 611 | 0.110 |
Why?
|
Prospective Studies | 11 | 2024 | 54137 | 0.110 |
Why?
|
Colon, Sigmoid | 1 | 2014 | 124 | 0.110 |
Why?
|
DNA Cleavage | 1 | 2013 | 56 | 0.110 |
Why?
|
Stromal Cells | 1 | 2019 | 1326 | 0.110 |
Why?
|
SEER Program | 4 | 2019 | 1530 | 0.110 |
Why?
|
Mice, SCID | 1 | 2018 | 2626 | 0.110 |
Why?
|
Genomic Instability | 1 | 2017 | 704 | 0.110 |
Why?
|
Biocatalysis | 1 | 2013 | 170 | 0.110 |
Why?
|
Acids | 1 | 2013 | 125 | 0.110 |
Why?
|
Carboplatin | 2 | 2015 | 788 | 0.110 |
Why?
|
Crystallography, X-Ray | 2 | 2008 | 1974 | 0.100 |
Why?
|
Cohort Studies | 10 | 2024 | 41256 | 0.100 |
Why?
|
Mutant Proteins | 2 | 2013 | 491 | 0.100 |
Why?
|
Protein Structure, Quaternary | 2 | 2010 | 428 | 0.100 |
Why?
|
Urothelium | 1 | 2014 | 277 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6313 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2018 | 3615 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2013 | 10146 | 0.100 |
Why?
|
Genome | 1 | 2020 | 1739 | 0.100 |
Why?
|
Immunohistochemistry | 3 | 2021 | 11070 | 0.090 |
Why?
|
Cell Division | 1 | 2018 | 4458 | 0.090 |
Why?
|
Evaluation Studies as Topic | 1 | 2013 | 1628 | 0.090 |
Why?
|
Hydroxyurea | 1 | 2012 | 282 | 0.090 |
Why?
|
Protein Kinases | 1 | 2018 | 1610 | 0.090 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2015 | 487 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 586 | 0.090 |
Why?
|
Ultracentrifugation | 1 | 2010 | 183 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3941 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2551 | 0.090 |
Why?
|
Arginine | 1 | 2013 | 933 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2013 | 549 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2020 | 9404 | 0.080 |
Why?
|
Rectum | 1 | 2014 | 895 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 1530 | 0.080 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 533 | 0.080 |
Why?
|
Binding Sites | 2 | 2008 | 6036 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 638 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3217 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 623 | 0.080 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1885 | 0.080 |
Why?
|
DNA Methylation | 2 | 2019 | 4373 | 0.080 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5779 | 0.080 |
Why?
|
Animals | 6 | 2024 | 167768 | 0.070 |
Why?
|
Radiometry | 1 | 2013 | 813 | 0.070 |
Why?
|
Substrate Specificity | 2 | 2013 | 1792 | 0.070 |
Why?
|
Cell Line | 2 | 2018 | 15591 | 0.070 |
Why?
|
Oligonucleotides | 1 | 2010 | 582 | 0.070 |
Why?
|
Mice | 3 | 2024 | 81101 | 0.070 |
Why?
|
Nucleic Acid Conformation | 2 | 2010 | 895 | 0.070 |
Why?
|
Germ Cells | 2 | 2022 | 635 | 0.070 |
Why?
|
Fluorouracil | 1 | 2012 | 1631 | 0.070 |
Why?
|
Crystallization | 1 | 2008 | 533 | 0.070 |
Why?
|
Genome, Human | 2 | 2018 | 4416 | 0.070 |
Why?
|
Risk Assessment | 6 | 2020 | 23884 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4312 | 0.070 |
Why?
|
Catalysis | 1 | 2008 | 772 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 8506 | 0.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1086 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3527 | 0.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1659 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2531 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5629 | 0.060 |
Why?
|
Visual Acuity | 1 | 2014 | 2642 | 0.060 |
Why?
|
Survival Rate | 4 | 2020 | 12721 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7843 | 0.060 |
Why?
|
Paclitaxel | 1 | 2012 | 1728 | 0.060 |
Why?
|
Logistic Models | 4 | 2020 | 13276 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5246 | 0.060 |
Why?
|
Radiography | 1 | 2014 | 6954 | 0.050 |
Why?
|
Androgens | 2 | 2021 | 1291 | 0.050 |
Why?
|
DNA Replication | 2 | 2022 | 1410 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2018 | 14354 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3076 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3570 | 0.050 |
Why?
|
Sequence Alignment | 1 | 2007 | 2176 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 39872 | 0.050 |
Why?
|
Adult | 10 | 2021 | 219935 | 0.050 |
Why?
|
Ribonuclease H | 1 | 2022 | 50 | 0.050 |
Why?
|
Propensity Score | 2 | 2021 | 1907 | 0.050 |
Why?
|
Genome, Bacterial | 1 | 2007 | 770 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2022 | 101 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6852 | 0.050 |
Why?
|
Orchiectomy | 1 | 2023 | 470 | 0.050 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12096 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3671 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2009 | 1460 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5404 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12440 | 0.050 |
Why?
|
BCG Vaccine | 1 | 2023 | 371 | 0.040 |
Why?
|
Age Factors | 2 | 2017 | 18358 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 155 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2912 | 0.040 |
Why?
|
Protein Structure, Tertiary | 1 | 2007 | 3796 | 0.040 |
Why?
|
Urethra | 1 | 2021 | 406 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2023 | 870 | 0.040 |
Why?
|
Catalytic Domain | 2 | 2013 | 705 | 0.040 |
Why?
|
Geography | 1 | 2021 | 660 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2500 | 0.040 |
Why?
|
Risk Factors | 5 | 2019 | 73809 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4876 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2018 | 192 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2022 | 17768 | 0.040 |
Why?
|
Pelvis | 1 | 2022 | 743 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 778 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6493 | 0.040 |
Why?
|
Drug Synergism | 1 | 2021 | 1745 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2017 | 77 | 0.040 |
Why?
|
Probability | 1 | 2022 | 2467 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2020 | 719 | 0.030 |
Why?
|
Anal Canal | 1 | 2019 | 372 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4901 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1218 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 370 | 0.030 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 419 | 0.030 |
Why?
|
Infant | 2 | 2014 | 36055 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15399 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2007 | 13447 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2416 | 0.030 |
Why?
|
Child, Preschool | 2 | 2014 | 42062 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2020 | 2850 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2925 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1705 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2007 | 17617 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 765 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1956 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2608 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1887 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1355 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6768 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15225 | 0.020 |
Why?
|
Molecular Imaging | 1 | 2018 | 815 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1737 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2014 | 1165 | 0.020 |
Why?
|
Gene Silencing | 1 | 2017 | 1507 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20500 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2019 | 3156 | 0.020 |
Why?
|
Incidence | 2 | 2022 | 21272 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5862 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1404 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2621 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4902 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 2497 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1740 | 0.020 |
Why?
|
Endometrial Neoplasms | 1 | 2018 | 1357 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2017 | 1894 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7502 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2600 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5490 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2886 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2379 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3675 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9599 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3915 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3765 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3175 | 0.020 |
Why?
|
Odds Ratio | 1 | 2019 | 9650 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10416 | 0.020 |
Why?
|
Kinetics | 1 | 2013 | 6371 | 0.020 |
Why?
|
United States | 3 | 2018 | 72136 | 0.020 |
Why?
|
Mutagenesis | 1 | 2009 | 1233 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 3709 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2010 | 3593 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 12945 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15651 | 0.010 |
Why?
|
Lung | 1 | 2021 | 9985 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2017 | 12759 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18119 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8297 | 0.010 |
Why?
|
Disease Progression | 1 | 2018 | 13468 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10171 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20055 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8611 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16534 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15773 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9460 | 0.010 |
Why?
|
Young Adult | 1 | 2013 | 58808 | 0.000 |
Why?
|
Child | 1 | 2013 | 79818 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 87892 | 0.000 |
Why?
|